ESC Premium Access

Blood Pressure Levels for Initiation of Antihypertensive Drug Therapy and Targets of Blood Pressure Lowering in Intermediate Risk People without Cardiovascular Disease: Insights from the HOPE-3 Trial

Topic: Treatment of hypertension

Congress Presentation

About the speaker

Professor Eva Lonn

Population Health Research Institute, Hamilton (Canada)
2 presentations
0 follower

5 more presentations in this session

Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen of Naproxen

Speaker: Professor S. Nissen (Cleveland, US)


Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial

Speaker: Professor S. Nicholls (Melbourne, AU)


Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects WithElevated Risk

Speaker: Professor T. Pedersen (Oslo, NO)


Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery: A sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)


One year clinical outcome of Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.

Speaker: Doctor V. Roolvink (Zwolle, NL)


Access the full session

Clinical Trial Update 2

Speakers: Professor E. Lonn, Professor S. Nissen, Professor S. Nicholls, Professor T. Pedersen, Professor S. Verma...

About the event


ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb